NBM
彥臣生技藥品股份有限公司
NBM is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is NBM-BMX (Phase 1 / Phase 2; recruiting, Malignant Neoplasm of Brain), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| NBM-BMX | — | Phase 1 / Phase 2; recruiting | Malignant Neoplasm of Brain | Taiwan | 2026-05-06 | Trial registry |
| NW-Si-2502 | — | — | — | — | 2026-04-30 | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.